Site menu

Search by ticker code:
Generic filters

Menu

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Mesoblast Capital Raising- Share Price Falls 10%

Shares in Mesoblast Limited (ASX: MSB) fell as much as 10% this morning after the company successfully completed a $75 million capital raising.

Who Is Mesoblast?

Mesoblast is a world leader in the development of allogeneic (off-the-shelf) cellular medicines. The company has leveraged its proprietary cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Mesoblast has facilities in Melbourne, New York, Singapore and Texas and is listed on both the ASX and the Nasdaq in the U.S.

Capital Raising

For those unfamiliar, the video below explains what a capital raising is:

In an announcement released to the ASX this morning, Mesoblast said it had successfully completed an institutional share placement that has raised $75 million.

The placement will result in the issuance of an additional 37.5 million shares at a price of $2.00 per share. This represents a 7% discount to the last closing price.

As was to be expected, the Mesoblast share price fell this morning moving closer to the issue price of $2. The share price briefly fell to a low of $1.92, before recovering somewhat to be trading at $1.98 at the time of writing.

The proceeds from the capital raising will be primarily used to build inventory, along with a targeted US sales force in preparation for the potential launch of remestemcel-L, a product for the treatment of aGVHD (acute graft versus host disease).

Management Comments

Commenting on the institutional share placement, CEO Dr Silviu Itescu said: “We are very pleased with the significant broadening of our institutional register and the strong continued support from our existing shareholders, with demand exceeding the funds raised. Mesoblast is well funded to execute the commercial strategy for potential launch of its first allogeneic cell therapy in the United States.”

Highly Speculative

Mesoblast looks to be a company with great potential and its share price rocketed last month after announcing a new strategic partnership. Although it’s easy to get swept up by a great story, it’s important that as investors, we take a commonsense approach to investing in small growth companies.

Despite its obvious potential, Mesoblast is not yet profitable and there is no clear indication that it will be in the near future. As a result, I think the current market cap of just under $1 billion is a bit of a stretch.

My preference would be to find companies that have proven products and have already crossed the line of profitability, with an ability to scale up quickly. It might mean that you miss the initial share price appreciation, but it also strips out a lot of the execution risk.

[ls_content_block id=”14947″ para=”paragraphs”]

At the time of publishing, Luke has no financial interest in any companies mentioned.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content